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Abstract 
Background: Mutations in leucine rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s dis‑
ease (PD). Mitochondrial and autophagic dysfunction has been described as etiologic factors in different experimental 
models of PD. We aimed to study the role of mitochondria and autophagy in LRRK2G2019S‑mutation, and its relationship 
with the presence of PD‑symptoms.
Methods: Fibroblasts from six non‑manifesting LRRK2G2019S‑carriers (NM‑LRRK2G2019S) and seven patients with 
LRRK2G2019S‑associated PD (PD‑LRRK2G2019S) were compared to eight healthy controls (C). An exhaustive assessment of 
mitochondrial performance and autophagy was performed after 24‑h exposure to standard (glucose) or mitochon‑
drial‑challenging environment (galactose), where mitochondrial and autophagy impairment may be heightened.
Results: A similar mitochondrial phenotype of NM‑LRRK2G2019S and controls, except for an early mitochondrial depo‑
larization (54.14% increased, p = 0.04), was shown in glucose. In response to galactose, mitochondrial dynamics of 
NM‑LRRK2G2019S improved (− 17.54% circularity, p = 0.002 and + 42.53% form factor, p = 0.051), probably to maintain 
ATP levels over controls. A compromised bioenergetic function was suggested in PD‑LRRK2G2019S when compared to 
controls in glucose media. An inefficient response to galactose and worsened mitochondrial dynamics (− 37.7% mito‑
chondrial elongation, p = 0.053) was shown, leading to increased oxidative stress. Autophagy initiation (SQTSM/P62) 
was upregulated in NM‑LRRK2G2019S when compared to controls (glucose + 118.4%, p = 0.014; galactose + 114.44%, 
p = 0.009,) and autophagosome formation increased in glucose media. Despite of elevated SQSTM1/P62 levels of 
PD‑NMG2019S when compared to controls (glucose + 226.14%, p = 0.04; galactose + 78.5%, p = 0.02), autophagosome 
formation was deficient in PD‑LRRK2G2019S when compared to NM‑LRRK2G2019S (− 71.26%, p = 0.022).
Conclusions: Enhanced mitochondrial performance of NM‑LRRK2G2019S in mitochondrial‑challenging conditions and 
upregulation of autophagy suggests that an exhaustion of mitochondrial bioenergetic and autophagic reserve, may 
contribute to the development of PD in LRRK2G2019S mutation carriers.
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Background
Parkinson’s disease (PD) is the second most prevalent 
neurodegenerative disease. While most of PD cases are 
idiopathic, monogenic forms of the disease are demon-
strated in about 5–10% of patients [1]. Mutations in leu-
cine-rich repeat kinase 2 (LRRK2) are the most common 
cause of inherited PD and account for 1–2% of sporadic 
PD cases [2]. LRRK2 is a large multi-domain protein 
with kinase and GTPase activity involved in several cel-
lular functions [3]. A glycine to serine substitution in the 
kinase domain of this protein (G2019S), accounts for the 
majority of genetically-transmitted, late-onset PD and for 
a variable proportion of sporadic PD, with higher preva-
lence in Ashkenazi Jews and North-African populations 
[4, 5]. Previous experimental models of PD have reported 
that LRRK2 mutations play a role in α-synuclein phos-
phorylation and depot, microtubule dynamics regulation, 
alterations in the ubiquitin–proteasome system and in 
neurite growth and branching of neurons [6].
Current evidence suggests that the increased 
kinase activity caused by the LRRK2G2019S-mutation 
(LRRK2G2019S), associated with the regulation of mito-
chondrial dynamics, vesicle trafficking and chaperone 
mediated autophagy [7–9], plays a pivotal role in the 
pathogenesis of LRRK2G2019S-associated PD, but the 
molecular mechanisms leading to neurodegeneration 
remain largely unknown [10].
Neuronal function is strongly dependent on oxida-
tive metabolism and efficient organelle clearance, and 
mitochondrial homeostasis greatly depends on adequate 
mitochondrial dynamics, turnover and renewal through 
autophagy, which makes the study of mitochondrial 
function and autophagy highly relevant in the elucidation 
of pathological pathways leading to neurodegeneration 
[7, 8]. Recent studies have characterized mitochondrial 
dysfunction and autophagy impairment in LRRK2G2019S-
associated PD [9–11]. Furthermore, therapeutic strate-
gies in LRRK2G2019S-associated PD consisting of drug 
testing in experimental models directed to reverse mito-
chondrial alterations, and LRRK2 inhibition as a thera-
peutic target for impaired autophagy in PD, have been 
tested with positive outcomes [12–14]. However, whether 
mitochondrial and autophagic alterations are cause or 
effect of the pathophysiology of LRRK2G2019S PD is still 
unclear.
In this regard, the study of LRRK2G2019S-carriers 
without PD symptoms (NM-LRRK2G2019S) in con-
trast to LRRK2G2019S-carriers diagnosed with PD (PD-
LRRK2G2019S), provides the opportunity to investigate 
early molecular alterations in this condition [6]. Motor 
symptoms of PD appear when loss of more than 60–70% 
of dopaminergic neurons has occurred, preceded by 
several years of neurodegeneration at different levels, and 
followed by a rapid progression of the disease [15]. In the 
last decade, research has focused on clinical and molecu-
lar alterations in the prodromal phase of PD [16] and in 
asymptomatic carriers of PD-linked mutations [14, 17], 
all of which has raised a great interest in the search of the 
disease aetiology, novel biomarkers and potential targets 
to prevent and modify the natural history of the disease.
Since the central nervous system is not readily avail-
able for investigation, several experimental models have 
been developed in the pursuit of unravelling PD patho-
physiology [15, 16]. Past studies have provided evidence 
of molecular alterations of PD in peripheral tissues 
[18–20], such as skin-derived fibroblasts, where defined 
mutations and cumulative cellular damage of donors are 
present [21]. Concerns have risen about the use of toxic 
insults and non-physiologic metabolic conditions in pre-
vious cell or animal models of the disease, which may not 
reproduce the mitochondrial and autophagic derange-
ments that lead to neurodegeneration. Glucose promotes 
anaerobic glycolysis in detriment of oxidative mitochon-
drial metabolism, thus masking potential bioenergetic 
alterations and consequent autophagic fails which may be 
more evident in mitochondrial-challenging conditions. 
In this sense, the use of galactose has been proved use-
ful in the study of primary mitochondrial diseases, since 
it enhances mitochondrial metabolism, evidencing pre-
existent mitochondrial alterations [22] and autophagic 
derangements.
In the present study, we hypothesized that mitochon-
drial and autophagic alterations represent a primary 
and systemic process in PD, which may play a role in the 
development of symptoms of LRRK2G2019S-associated 
PD, and that such derangements may be exacerbated in 
mitochondrial-challenging conditions. Consequently, we 
evaluated the mitochondrial and autophagic phenotype 
in fibroblasts from NM-LRRK2G2019S subjects and PD-
LRRK2G2019S patients, either in glycolytic or oxidative 
conditions enabled by the use of galactose.
Methods
Study design and population
A single-site, cross-sectional, observational study was 
conducted. Twenty-one age and gender paired sub-
jects were included: six NM-LRRK2G2019S, seven PD-
LRRK2G2019S, and eight healthy, unrelated controls (C). 
All PD-LRRK2G2019S patients met the UK Brain Bank 
Criteria for PD [23]. Control group included LRRK2G2019S 
negative relatives of patients who voluntarily underwent 
skin biopsy. Subjects with comorbidities, mitochondrial 
disorders, and those consuming mitochondrial toxic 
drugs were not included in any of those groups [24].
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Fibroblasts culture
Fibroblasts were obtained by a skin punch biopsy 
and mutation screening was performed as previously 
described [5].
Cells were grown in 25  mM glucose DMEM medium 
(Gibco, Life Technologies) supplemented with 10% heat-
inactivated fetal bovine serum and 1% penicillin–strep-
tomycin at 37 °C, in a humidified 5%  CO2 air incubator, 
until 80% optimal confluence was reached. In order to 
assess whether mitochondrial and autophagic function 
was directly implicated in the pathogeny of LRRK2G2019S, 
cells were exposed for 24-h to either 25  mM glucose 
(standard) or 10 mM galactose (mitochondrial-challeng-
ing) media [22], where cells are forced to rely on oxidative 
phosphorylation for ATP production. Fibroblasts were 
harvested with 2.5% trypsin, (Gibco, Life technologies™) 
at 500 g for 8 min. In vivo experiments, including oxygen 
consumption and mitochondrial membrane potential 
(MMP), were performed in parallel including one subject 
from each cohort, at the same passage, both in glucose 
and galactose media. Fixation of cells for immunofluores-
cent quantification of mitochondrial dynamics was also 
performed at this time point. Cell pellets from each line 
were kept at − 80 °C for further experimental procedures. 
All functional assays were performed in cells between 
passage 5 and 10.
Experimental parameters
In order to address an exhaustive mitochondrial pheno-
typing and autophagic print, this study contemplated the 
following experiments:
Mitochondrial phenotype
a. Mitochondrial DNA, RNA and protein content:
 Total DNA was extracted by standard phenol chlo-
roform procedure and total RNA was extracted by 
affinity microcolumns and retro transcribed to cDNA 
in triplicates, as reported elsewhere [25]. Mitochon-
drial DNA and RNA content were measured as the 
ratio between a mtDNA encoded gene/transcript 
and a nuclear encoded one (mt12SrRNA/nRNAseP). 
Mitochondrial protein content was assessed by West-
ern Blot in duplicates, through 7/13% SDS-PAGE and 
immunoquantification of nuclear-encoded VDAC, 
mitochondrial-encoded COXII, and nuclear-encoded 
COXIV analysis, normalized by β-actin. Chemilumi-
nescence was quantified with ImageQuantLD® [26].
b. Mitochondrial function:
i. Mitochondrial respiratory chain (MRC) enzyme 
activities previously associated to PD [14] were 
measured by spectrophotometry, following Span-
ish standardized national procedures (unpub-
lished data). Complex I (CI) and Complex IV 
(CIV) enzyme activities were then normalized by 
citrate synthase (CS), widely considered as a reli-
able marker of mitochondrial content.
ii. Mitochondrial respiration is the result of oxygen 
consumption by the MRC. CI stimulated oxygen 
consumption was assessed through pyruvate-
malate oxidation (PMox) by high-resolution 
respirometry using Oroboros™ Oxygraph-2K® 
(Innsbruck, Austria) in permeabilized fibroblasts, 
following manufacturer protocols [27].
iii. Total cellular ATP was measured in duplicates by 
using the Luminescent ATP detection assay kit® 
#ab113849; Abcam™ (Cambridge, United King-
dom), according to manufacturer’s instructions, 
in order to quantify the bioenergetic efficiency of 
MRC.
iv. Mitochondrial damage markers were measured 
to search for mitochondrial lesion in association 
with the presence of LRRK2G2019S Mitochon-
drial membrane potential was measured by flow 
cytometry twice to establish whether punctual 
mitochondrial alterations in MMP prelude mito-
chondrial dysfunction, as previously described 
[28]. Second, lipid peroxidation was meas-
ured in duplicates by the spectrophotometric 
measurement of malondialdehyde (MDA) and 
4-hydroxyalkenal (HAE), as indicators of oxida-
tive damage of reactive oxygen species (ROS) into 
cellular lipid compounds, as reported elsewhere 
[29]. Finally, to evaluate the apoptotic rate, cells 
were double-stained for annexin V and propid-
ium iodide and quantified by flow cytometry, as 
previously reported [30].
c. Mitochondrial dynamics has been shown to be cru-
cial in the maintenance of mitochondrial homeosta-
sis, and LRRK2 has been suggested to play a role in 
mitochondrial fission [31]. Immunocytochemistry 
using confocal microscopy was performed as previ-
ously described [32]. One cell from three different 
fields for each cell line were randomly selected and 
analyzed with Image J [33] software to quantify the 
following parameters of mitochondrial dynamics:
i. Mitochondrial network or mitochondrial con-
tent: Total number of mitochondria/total cell 
area [34]; higher mitochondrial network values 
are considered a sign of healthy mitochondria.
ii. Circularity (Circ) or mitochondrial isolation: 
4π.area/perimeter2; circular mitochondria have 
less interaction sites with other mitochondria, 
thus, Circ = 1 refers to poor mitochondrial 
dynamics of isolated mitochondria.
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iii. Aspect ratio (AR) or mitochondrial elongation: 
major/minor axis, AR = 1 indicates a perfect cir-
cle; AR increases as mitochondria elongate and 
become more elliptical, which is considered a 
beneficial sign of mitochondrial dynamics.
iv. Form factor (FF) or mitochondrial branch-
ing: Circ-1; FF = 1 corresponds to a circular, 
unbranched mitochondrion and high FF values 
indicate branched and connected mitochondria, 
which is favourable for mitochondrial function.
Autophagic print
Characterization of autophagic print was carried out 
twice by quantitative measurement of autophagic-
related proteins in both media (basal). To further assess 
autophagosome formation, 100  nM Bafilomycin A1 
was added at two different time points (4 and 8 h) [35]. 
Briefly, fibroblasts were lysed with RIPA buffer and pro-
tease inhibitors followed by centrifugation at 14,000g at 
4  °C for 5  min. Soluble fraction was retained for West-
ern Blot analysis. Equal protein load lysates were resolved 
through 7/15% SDS-PAGE and transferred into nitrocel-
lulose membranes, following blocking with 10% skimmed 
milk. Membranes were hybridized with Anti-SQSTM1/
p62 and anti-LC3B antibodies overnight at 4 °C. Protein 
expression was normalized by β-actin protein content in 
all cases, as a cell loading control. Chemiluminescence 
was quantified with ImageQuantLD® and results were 
expressed and interpreted as:
i. Autophagy substrate; (SQSTM/p62)/β-actin is a 
cargo protein widely used as a marker of autophagy 
initiation [13].
ii. Autophagy receptor (LC3BI/β-actin) and lipidated 
form of the autophagy receptor (LC3BII/β-actin): 
LC3B is a marker of autophagosomes; LC3BI is 
unspecific and expressed in the autophagosome 
membrane but can also be located in cytoplasm or 
other organelles, its lipidation and migration to the 
autophagosome membrane (LC3BII) is considered to 
be a marker of autophagosome formation [36].
Immunocytochemistry was performed to further char-
acterize autophagosome formation in the basal state, 
in glucose and galactose media, and after 6  h exposure 
to 100  nM Bafilomycin A1 using confocal microscopy. 
Briefly, cultured skin fibroblasts were washed with PBS 
before fixation with 4% paraformaldehyde for 15  min. 
Fixed cells were washed, permeabilized with 0.1% Digi-
tonin in blocking solution (1% bovine serum albu-
min). Cells were incubated for 1 h using Anti-LC3 pAB. 
Counterstaining with DAPI was performed for nucleus 
visualization.
Experimental parameters were normalized by protein 
levels, measured by the BCA assay in quadruplicates, 
when needed. See Additional file 1: Material and meth-
ods for detailed protocols and reagents.
Statistical analysis
Results were expressed as mean ± SEM and as a percent-
age of increase/decrease with respect to controls, which 
were arbitrarily assigned as a 0% baseline. Two statistical 
approaches were performed for each media (glucose or 
galactose): (i) Non-parametric Mann–Whitney analysis 
for independent samples to detect inter-group differ-
ences for individual parameters and (ii) principal com-
ponent analysis (PCA) to define the component with the 
largest possible variance and to show whether the stud-
ied population would be clustered by group, age or sex. 
Statistical analysis was performed with SPSS 20.00 (for 
Mann–Whitney test) and the R programming language 
version 3.4.3 and its missMDA, package (for PCA) [37]. 
Statistical significance was set at p < 0.05 in all cases.
Results
Epidemiological data of the studied cohorts at the time of 
skin biopsy are shown in Table 1 and clinical characteris-
tics of PD-LRRK2G2019S patients are shown in Additional 
file  2: Table  S1. As expected, no significant differences 
in age and gender between groups were evidenced by 
either Mann–Whitney or PCA tests. None of the NM-
LRRK2G2019S subjects had developed clinical symptoms 
of the disease at the time of results analysis. Groups 
were not differentially clustered nor variables correlated 
Table 1 Epidemiological characteristics of the cohorts
Epidemiological data of the studied cohorts at the time of skin biopsy. No significant differences were found in age or gender between groups
NM‑LRRK2G2019S: Non‑manifesting LRRK2G2019S‑mutation carriers; PD‑LRRK2G2019S: patients with LRRK2G2019S‑mutation and clinically manifest PD; N: Number of cases 
enrolled; SEM: Standard error of the mean
Group N Gender Age (years)
Male Female Range Mean SEM
NM‑LRRK2G2019S 6 3 (50%) 3 (50%) 34–61 46.67 4.04
PD‑LRRK2G2019S 7 3 (42.85%) 4 (57.15%) 44–71 60.57 3.15
Control 8 3 (37.50%) 5 (62.50%) 41–69 56.00 3.63
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among each other by performing PCA (Additional file 3: 
Figure S1).
Mitochondrial phenotype
Figure  1 summarizes mitochondrial phenotype and raw 
data of experimental parameters is provided in Addi-
tional file  4: Table  S2. Extended versions of graphics 
corresponding to genetics and mitochondrial protein 
synthesis can be found in Additional file 5: Figure S2. 
a. Mitochondrial function of NM-LRRK2G2019S ame-
liorated when subjected to mitochondrial challeng-
ing conditions, in order to maintain ATP production 
over controls.
 Mitochondrial parameters were preserved in NM-
LRRK2G2019S subjects in glucose media with respect 
to controls except for early MMP depolarization 
(54.14%, p = 0.04, Figs.  1a.8 and 2f ) and increased 
mitochondrial network (38.32%, p = 0.04, Figs. 1a.11 
and 3b). 
 After galactose exposure, CI enzymatic function,  O2 
consumption stimulated for CI, CIV enzymatic func-
tion and ATP levels of NM-LRRK2G2019S trended to 
overcome the level of controls (76.92, 76.87, 88.48 
and 61.98%; p = 0.18, p = 0.35, p = 0.14 and p = 0.76, 
respectively), suggesting an adaptation to mito-
chondrial challenging conditions (Figs.  1a.4–7 and 
2b–e). Mitochondrial dynamics ameliorated in fibro-
blasts of NM-LRRK2G2019S with respect to controls 
when exposed to galactose medium, evidenced by 
17.54% decreased circularity (p = 0.002) and 42.53% 
increased form factor (p = 0.051) (Fig.  1a.12, 14), 
accounting for longer, more branched mitochondria 
(Fig. 3c and e).
b. PD-LRRK2G2019S showed mitochondrial alterations in 
glucose media, which were worsened when subjected 
to mitochondrial-challenging conditions, resulting in 
increased oxidative stress.
 In fibroblasts from PD-LRRK2G2019S patients in glu-
cose media, CI enzyme function,  O2 consumption 
stimulated for CI and ATP levels seemed to decrease 
with respect to controls (Figs. 1b.4, 5, 7 and 2b, c and 
e). Noticeably, although not significantly, depolar-
ized mitochondria augmented to 101.34% (p = 0.14), 
accompanied by a 90% increase of oxidative stress 
(p = 0.46) with respect to controls (Figs. 1b.8, 9 and 
2f, g).
 Exposure of PD-LRRK2G2019S fibroblasts to galac-
tose media increased CI enzyme function compared 
to controls (84.62%, p = 0.04), but such increase 
was neither translated into heightened oxygen con-
sumption, nor enhanced CIV enzyme function or 
ATP synthesis (Figs.  1b.4, 7 and 2b–e), as formerly 
observed in asymptomatic carriers. Instead, oxida-
tive damage increased 144.64% (p = 0.13) (Figs. 1b.9 
and 2g) and, in detriment to mitochondrial dynam-
Fig. 1 Mitochondrial phenotype of LRRK2G2019S‑mutation carriers. 
Mitochondrial parameters measured in LRRK2G2019S‑mutation 
carriers, without clinical symptoms of PD (NM‑LRRK2G2019S) or with 
clinically manifest PD (PD‑LRRK2G2019S) represented as a percentage 
of decrease/increase when compared to healthy controls, arbitrarily 
assigned as 0% (black, dotted line) in glucose (blue line) and 
galactose media (red line). The letters (a), (a’), (b) and (b’), indicate 
those cases in which a statistical difference within the two analysed 
groups and controls was found: (a) p < 0.05 when comparing 
NM‑LRRK2G2019S to controls in glucose media, (a’) p < 0.05 when 
comparing NM‑LRRK2G2019S to controls in galactose media, (b) p < 0.05 
when comparing PD‑LRRK2G2019S to controls in glucose media and 
(b’) p < 0.05 when comparing PD‑LRRK2G2019S to controls in galactose 
media. In summary, fibroblasts of NM‑LRRK2G2019S showed a pattern 
similar to controls in glucose, except for early disruption of MMP. 
When subjected to mitochondrial challenging conditions, global 
mitochondrial function and dynamics trended to ameliorate, towards 
ATP production (A). Fibroblasts of PD‑LRRK2G2019S in glucose trended 
towards a deranged mitochondrial function when compared 
to controls. When subjected to galactose media, PD‑LRRK2G2019S 
fibroblasts presented an inefficient increase of mitochondrial 
function and worsened mitochondrial dynamics, leading to increased 
oxidative stress (B)
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ics, aspect ratio decreased 37.7% (p = 0.053) after 
exposure to mitochondrial challenging conditions 
(Figs. 1b.13 and 3d).
Autophagy
Figure  4 summarizes the autophagic characterization, 
and raw data of experimental parameters is provided in 
Additional file 4: Table S2.
a. Autophagy initiation signalling increased in NM-
LRRK2G2019S subjects in glucose and galactose media, 
but autophagosome formation was only upregulated 
in glucose media.
 A significant increase in autophagy substrate 
expression (SQSTM1/p62) in fibroblasts of NM-
LRRK2G2019S was observed when compared to con-
trols in glucose media (118.4%, p = 0.014), and in 
galactose, after 4 h of bafilomycin exposure (114.44% 
increase, p = 0.009) (Fig.  4c). These increased sig-
nalling for autophagy initiation was accompanied 
by trends to increase autophagosome formation at 
4 and 8  h of bafilomycin treatment (LC3BII/βactin: 
+ 145.22% and + 287.21%, respectively, p = 0.051) 
when compared to controls in glucose media, but not 
in galactose media, where autophagosome formation 
seemed to be decreased (Fig. 4d).
b. Autophagosome formation was decreased in PD-
LRRK2G2019S despite increased autophagy initiation 
in both media.
 Autophagy substrate expression was increased in 
PD-LRRK2G2019S after 8  h of bafilomycin treatment 
in glucose media (226.14%., p = 0.04) and at 4  h in 
galactose media when compared to controls (78.5%, 
p = 0.02) (Fig.  4c). However, these increased signal-
ling for autophagy initiation was not accompanied 
by autophagosome formation in any media, and a 
significant decrease in LC3BII levels was demon-
strated when compared to NM-LRRK2G2019S sub-
jects at 4 and 8 h of bafilomycin treatment in glucose 
media (− 79 to 86%, p = 0.042 and − 71.26%, p = 0.22 
respectively) (Fig. 4d).
Discussion
The main contribution of this study was the exhaustive 
analysis of mitochondrial phenotype and autophagic 
print of fibroblasts from LRRK2G2019S mutation carri-
ers with and without clinical evidence of parkinsonism 
in glucose and galactose media. Briefly, this study sug-
gests that the exhaustion of mitochondrial bioener-
getic and autophagic reserve play a role in the onset of 
LRRK2G2019S-associated PD.
Mainly, in standard conditions (glucose), the NM-
LRRK2G2019S fibroblasts showed a preserved mitochon-
drial phenotype, except for a significant disruption of 
MMP that may represent an early event in PD [14, 38–
40]. In response to mitochondrial-challenging condi-
tions (galactose), a pattern of mitochondrial enzymatic 
and respiratory function enhancement was observed, 
resulting in an increase of ATP production and morpho-
logical features characteristic of improved mitochondrial 
dynamics. In PD-LRRK2G2019S fibroblasts, bias toward 
deranged mitochondrial phenotype were found in glu-
cose media, such as decreased CI enzyme function, oxy-
gen consumption and ATP production, and increased 
oxidative stress. Exposure to galactose revealed an inef-
ficient increase in mitochondrial function, trends to 
increase oxidative stress and deranged mitochondrial 
dynamics. The most differential response between NM-
LRRK2G2019S subjects and PD-LRRK2G2019S patients in 
mitochondrial functional and dynamic parameters was 
shown in response to mitochondrial-challenging condi-
tions. In accordance to literature, mitochondrial defects 
were evidenced in galactose media [22], which leads us 
to hypothesize that, given their oxidative metabolism and 
postmitotic nature, neurons may be permanently dam-
aged by mitochondrial and autophagic alterations that in 
peripheral tissues may be negligible [41, 42]. Ergo, a defi-
cient mitochondrial functional reserve may underlie the 
(See figure on next page.)
Fig. 2 Mitochondrial function. Results are represented by mean ± SEM, comparing controls (n = 8; white bars), NM‑LRRK2G2019S‑mutation, (n = 6; 
grey bars) and PD‑LRRK2G2019S (n = 7; black bars) in glucose and galactose media. a Citrate synthase levels remained constant between groups in 
both media. b A trend to decrease CI enzymatic activity in NM‑LRRK2G2019S and PD‑LRRK2G2019S was observed in glucose media, and PD‑LRRK2G2019S 
patients harbouring the mutation increased their activity with respect to controls in galactose media (p = 0.04). c Oxygen consumption trended to 
reproduce the pattern of CI enzymatic activity. After exposure to galactose media, a non‑significant increment in  O2 consumption was observed in 
fibroblasts of NM‑LRRK2G2019S subjects with respect to controls (p = 0.35). d Complex IV enzymatic function remained similar in all groups, showing 
a trend to increase in NM‑LRRK2G2019S subjects with respect to controls in glucose and galactose media (p = 0.14 in both cases). e ATP levels tended 
to decrease in both groups in glucose media (p = 0.18 when comparing PD‑LRRK2G2019S with controls). f Number of depolarized mitochondria was 
increased in NM‑LRRK2G2019S when compared to controls in glucose media (p = 0.04), with the same trend observed for PD‑LRRK2G2019S although 
without reaching statistical significance (p = 0.14). g Oxidative damage trended to increase in PD‑LRRK2G2019S patients in both conditions when 
comparing them to controls. h Apoptotic rate tended to decrease in the NM‑LRRK2G2019S group in both media
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onset of LRRK2G2019S-associated PD. The link between 
mitochondrial health and autophagy initiation may be 
deduced from these findings, but needs to be assessed in 
more detail.
Recent reports have described differential mitochon-
drial functional phenotypes in idiopathic and some 
monogenic forms of PD [43–45]. Our study partially 
reproduces the mitochondrial phenotype described by 
Mortiboys et  al. [17], where CI enzyme activity, oxygen 
consumption and ATP levels progressively decreased 
in NM-LRRK2G2019S and PD-LRRK2G2019S. Papkovskaia 
et al. [39] also found decreased ATP levels and depolari-
zation in fibroblasts of PD-LRRK2G2019S.
Oxidative stress is a hallmark of mitochondrial involve-
ment on PD and neurodegeneration [11, 46]. Our results 
are in accordance with Grünewald et al. [40], who found 
increased levels of the antioxidant superoxide dismutase, 
but no significant alteration of oxidative stress in fibro-
blasts of NM-LRRK2G2019S, suggesting the existence of 
compensatory mechanisms against early-stage produc-
tion of ROS. Liou et al. [47], reported a protective effect 
against oxidative stress-mediated apoptosis mediated by 
wild type LRRK2 which is lost in PD-associated muta-
tions. In our study, trends towards reduced apoptosis in 
NM-LRRK2G2010S in spite of increased oxidative stress 
was found, which suggests the existence of other protect-
ing mechanisms that are yet to be described.
This study corroborated the impairment in mitochon-
drial dynamics in PD-LRRK2G2019S patients described by 
others [17, 31, 40, 48]. Additionally, a healthier pattern 
in mitochondrial dynamics in NM-LRRK2G2019S subjects 
was demonstrated. Whether alterations in mitochondrial 
dynamics are the cause or consequence of mitochondrial 
dysfunction, and the mechanism by which LRRK2 medi-
ates such alterations, is still a matter of debate [3].
Trends towards upregulation in autophagy in NM-
LRRK2G2019S were observed, which may be explained by 
any of the previously described effects of LRRK2G2019S 
mutation in autophagy [49–51] or by an increased 
attempt to eliminate damaged sub cellular compounds. A 
further increase in autophagy initiation signalling in PD-
LRRK2G2019S patients was found, probably in response to 
mitochondrial dysfunction and the resulting decrease in 
ATP levels evidenced by galactose exposure [13, 52].
However, the inability to continue with autophagosome 
formation and closure, and the resulting accumulation of 
damaged mitochondria among other waste product of 
cell metabolism, may explain the pathologic state in this 
group. Further studies should confirm the present find-
ings, where mitophagy and autophagic flux may be char-
acterized in more detail [53].
This is the first study reporting that the exposition of 
fibroblasts from NM-LRRK2G2019S to mitochondrial 
challenging conditions tends to enhance mitochondrial 
performance, even above the values of controls. We 
hypothesize that such improvement represents a biologi-
cal rescue mechanism characteristic of NM-LRRK2G2019S, 
which may protect from the development of symptoms 
(See figure on next page.)
Fig. 4 Autophagy. a Representative images (original images have been cropped and are available at request) of autophagy markers measured 
by Western blot comparing: NM‑LRRK2G2019S: Non‑manifesting carriers of LRRK2G2019S‑mutation; PD‑LRRK2G2019S: patients with LRRK2G2019S‑mutation 
and clinically manifest PD. (SQSTM1/p62)/β‑actin: Autophagy substrate, LC3B‑I/β‑actin: autophagy receptor, basal form. LC3B‑II/β‑actin: 
autophagy receptor, lipidated form. b Representative images of autophagosome formation (UT) and accumulation after 8 h of treatment with 
100 nM bafilomycin (BAF) obtained by confocal microscopy. c, d Results are represented by mean ± SEM, comparing controls (n = 8; white bars), 
NM‑LRRK2G2019S‑mutation (n = 6, gray bars) and PD‑LRRK2G2019S (n = 7; black bars) in either glucose or galactose media and at basal state, and after 4 
and 8 h treatment with bafilomycin (0, 4, 8). Autophagy initiation was upregulated in NM‑LRRK2G2019S subjects in glucose and galactose media when 
compared to controls (+ 118.4% SQSTM1/P62, p = 0.014 and + 114.44% SQSTM1/P62, p = 0.009, respectively) and trends to increase autophagy 
substrate were observed in PD‑LRRK2G2019S in both media (c). Autophagosome formation trended to increase at 4 and 8 h of bafilomycin treatment 
in NM‑LRRK2G2019S and was significantly decreased in PD‑LRRK2G2019S when compared to NM‑LRRK2G2019S subjects in glucose media at 4 and 8 h of 
bafilomycin treatment (− 79 to 86%, p = 0.042 and − 71.26%, p = 0.22 respectively) (d)
Fig. 3 Mitochondrial dynamics. a Representative images of mitochondrial network obtained by confocal microscopy. NM‑LRRK2G2019S: 
Non‑manifesting carriers of LRRK2G2019S‑mutation; PD‑LRRK2G2019S: patients with LRRK2G2019S‑mutation and clinically manifest PD. b–e. Results 
are represented by mean ± SEM, comparing controls (n = 8; white bars), NM‑LRRK2G2019S (n = 5, gray bars) and PD‑LRRK2G2019S (n = 7; black bars) 
in glucose and galactose media. Briefly, in fibroblasts of NM‑LRRK2G2019S a significant increase in mitochondrial network in standard conditions 
(glucose) was observed when compared to controls (b). When NM‑LRRK2G2019S fibroblasts were subjected to mitochondrial challenging conditions 
(galactose), an improvement of mitochondrial dynamics was seen, by decreased circularity (c) and trends to increase form factor (e), accounting 
for longer, more branched mitochondria. Fibroblasts of PD‑LRRK2G2019S showed a pattern similar to controls in standard (glucose) conditions and a 
handicapped response when exposed to mitochondrial challenging conditions (galactose) as shown by decreased aspect ratio (d), accounting for 
shorter mitochondria
(See figure on previous page.)
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by compensating an increased bioenergetic cell demand 
or early mitochondrial damage. It may be deduced that 
mitochondrial and autophagic optimal function could 
have a protective role in mutation carriers who have not 
yet developed symptoms of PD. Mitochondria from NM-
LRRK2G2019S may retain the capacity to raise their activ-
ity until a maximal threshold beyond which PD clinical 
manifestations can appear.
On account of the above, our results suggest that 
LRRK2G2019S-mutation by itself may not determine the 
development of clinical manifest PD [2, 52, 54], in accord-
ance with other previous studies where NM-LRRK2G2019S 
subjects perform as good as controls in motor [18], neu-
ropsychological [55] and neuroimaging tests [56]. Scien-
tific efforts focused on promoting mitochondrial optimal 
performance and autophagy regulation should be trans-
lated into prophylactic measures which modify the natu-
ral history of PD.
In regard to the experimental model used in this study, 
the exposure to oxidative metabolism through galactose 
media unveiled a differential mitochondrial phenotype 
that may reproduce that of neurons. Herein, we suggest 
that alternative models of PD should also be tested in oxi-
dative conditions [41].
Some limitations in the present study must be acknowl-
edged. Although the study of rare forms of PD due to inher-
ited mutations reduces the potential study of bigger cohorts, 
the small sample size of this study may explain a common 
pitfall of the reported outcomes, which is the limited num-
ber of significant differences. Additionally, the inter-indi-
vidual variability in environmental conditions potentially 
influencing molecular parameters may also hinder the 
homogeneity of the distinct groups. There is a positive cor-
relation between age and PD onset in LRRK2G2019S muta-
tion carriers [2], suggesting that some NM-LRRK2G2019S 
may eventually develop PD. However, it must be empha-
sized that no age related differences in mitochondrial and 
autophagic parameters were observed. Finally, many other 
molecular triggers may be taking place in PD, where the 
loss of dopaminergic neurons may be the common mani-
festation of a complex disease where mitochondrial altera-
tions and autophagic deregulation are only one of manifold 
molecular events leading to neurodegeneration.
Conclusions
Enhanced mitochondrial performance of NM-
LRRK2G2019S in mitochondrial-challenging conditions 
and upregulation of autophagy suggests that an exhaus-
tion of mitochondrial bioenergetic and autophagic 
reserve, may contribute to the development of PD in 
LRRK2G2019S mutation carriers.
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